ZURA Reports $144M Offering Proceeds, $225.6M Cash, TibuSHIELD Phase 2 On Track Q4 2026 Data, TibuSURE Phase 2 On Track H1 2027 Data, Net Loss $24.2M, R&D $14.7M, G&A $10.8M, CEO Kulkarni Appointed Jan 2026, Board Adds Eisner & Nirula
Zura Bio Limited Class A Ordinary Shares · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $4.24
-9.3% in 7d after detection
Post-detection moves
1h
—
1d
+5.5%
3d
+4.6%
7d
-9.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS